Lilly Just Killed an Obesity Drug. That's Actually the Smart Move.

Pfizer killed its oral weight-loss pill danuglipron in April 2025 after a trial participant showed signs of drug-induced liver injury. That was actually the company's second attempt with the molecule; an earlier twice-daily version was scrapped in late 2023 because patients couldn't tolerate the nausea and vomiting. Pfizer later dropped yet another oral obesity candidate, citing the competitive landscape rather than any specific clinical problem.

Roche pulled the plug on CT-173 in July 2025 after deciding the drug simply wouldn't be differentiated enough to compete. Amgen shelved an early-stage program called AMG 513. Even Novo Nordisk, the company that essentially invented the modern obesity drug category, decided not to advance one of its own next-generation candidates.

The pattern is clear: losing weight isn't hard for these drugs anymore. Losing enough weight, with tolerable side effects, at a competitive price point, while offering something the market leaders don't already provide? That's the hard part.

Lilly's Real Game Plan

So why isn't Wall Street panicking? Because bimagrumab was a supporting actor, not the star. Analysts largely treated the discontinuation as smart portfolio management rather than a crisis.

And when you look at Lilly's full obesity pipeline, it's easy to see why. The company isn't betting on one horse. It's building a stable.

Orforglipron is the near-term play: an oral, once-daily GLP-1 pill that was FDA-approved on April 1, 2026 and launched via LillyDirect on April 6, 2026. It gives millions of patients a needle-free alternative to injectable obesity drugs. Lilly has also signaled that Medicare patients could pay as little as $50 per month.

Retatrutide is the big swing. It's a triple agonist (targeting GIP, GLP-1, and glucagon receptors simultaneously) with positive Phase 3 results reported in mid-2026. Lilly plans to file for FDA approval in early 2027. If approved, it could set a new efficacy ceiling for the entire class.

Then there's eloralintide, a selective amylin agonist that works through a completely different biological pathway than any GLP-1 drug. That's significant because it gives Lilly a potential option for patients who can't tolerate GLP-1 side effects, or who might benefit from combination therapy down the road.

The strategy is essentially: cover every angle. Oral pills for convenience. Next-gen injectables for maximum efficacy. Non-GLP-1 options for patients who need a different approach. Lilly even entered a multi-year research collaboration and exclusive worldwide license agreement with Nimbus for an early-stage small-molecule obesity program, betting on the science before it's fully baked.

The New Rules of Obesity R&D

Lilly's decision to kill bimagrumab tells us something important about where this market is heading. We've entered an era where the bar for a new obesity drug isn't just "does it work?" but "does it work well enough to justify its existence next to tirzepatide and semaglutide?"

That's a brutal filter. The 5% weight-loss threshold that used to define success is now table stakes; the real competition starts at 15% and the frontier is pushing past 20%. Any new entrant needs to beat the incumbents on efficacy, tolerability, convenience, or some combination of all three.

For smaller biotechs chasing the obesity space, this is a warning shot. The cost of a failed Phase 2 trial is one thing. The cost of succeeding in Phase 2 but still not being competitive enough to matter? That's a different kind of failure, and arguably a more expensive one.

Lilly saw that math and made the call. Rather than spend years and hundreds of millions advancing a program that might produce nice-to-have data but not must-have results, they redirected those resources toward candidates with higher ceilings.

The Bottom Line

Killing a drug program is usually bad news. But in the obesity market of 2026, knowing when to kill a program might be the most valuable skill a pharma company can have. Lilly didn't lose a product. It preserved its focus on the candidates that actually have a shot at defining the next generation of weight-loss treatment.

The obesity revolution isn't slowing down. If anything, it's speeding up. And in a race this fast, the smartest move sometimes isn't running harder. It's choosing the right lane.

Novo Nordisk Just Walked Away from a $285M Obesity Bet. Why?

Novo Nordisk just killed a $285 million partnership with Ascendis Pharma to develop a once-monthly GLP-1 obesity shot. In the middle of the biggest obesity drug race in history, why would you hand back that asset? The answer says a lot about where the market is heading.